Perceptions of Teachers, Parents and Adolescents about HPV, Cervical Cancer and HPV Vaccination

Backgroud: Cervical cancer is a common disease after breast cancer. That is caused by Human papillomavirus (HPV) and now, we have HPV vaccin to prevent the disease with objectives: to determine rate of correct knowledge, attitudes and practice towards HPV vaccination against cervical cancer of mothers who have daughters aged 1 to 26 years old in An Binh ward, Ninh Kieu district, Can Tho city and to determine the relationship between correct knowledge and correct attitudes and correct behaviors towards vaccination against cervical cancer of these mothers. Materials and method: Cross-sectional, community survey on 410 mothers who are interviewed face to face by using a questionnaire. Results: The rate of correct knowledge, attitude and practice towards HPV vaccination against cervical cancer is 4.4%; 89.5%; 12.2%; respectively. There’s a correlation between correct knowledge and correct behaviors towards vaccination against cervical cancer among mothers (p<0.05), but no correlation between correct knowledge and correct attitudes. Conclusion: the rate of mothers who have correct knowledge and behaviors is relatively low but whose correct attitude is high. Therefore, may be they want to know more information about vaccination against cervical cancer so that it should have appropriate information-education-counseling and health care campaign to community. Keywords: Knowledge, Attitude, practice, vaccine, Human papillomavirus, cervical

Download Full-text

HPV VACCINE AND CERVICAL CANCER

Journal of Medicine and Pharmacy ◽

10.34071/jmp.2011.3.15 ◽

2011 ◽

pp. 108-115

Author(s):

Vu Quoc Huy Nguyen

Keyword(s):

Cervical Cancer ◽

Relative Risk ◽

Hpv Vaccine ◽

Hpv Vaccination ◽

Preventive Strategy ◽

Protective Effects ◽

Papilloma Virus ◽

Vaccine Trials ◽

Close Relationship ◽

The Relationship

Persistent infection with high-risk Human Papilloma Virus (HPV) has been identified as the causal factor of cervical cancer, with relative risk up to 300-400 folds. This very close relationship leads to the preventive strategy of vaccination against HPV infections and HPV-related lesions. The article describes molecular and immunologic characteristics of HPV, currently available HPV vaccines and its protective effects; the relationship between HPV vaccination and cervical cancer screening, and an introduction to therapeutic HPV vaccine trials.

Download Full-text

Connective data: Markov chain models and the datafication of cervical cancer and HPV vaccination in Colombia

Tapuya Latin American Science Technology and Society ◽

10.1080/25729861.2021.1874744 ◽

2021 ◽

Vol 4 (1) ◽

pp. 1874744

Author(s):

Oscar Javier Maldonado Castañeda

Keyword(s):

Cervical Cancer ◽

Markov Chain ◽

Hpv Vaccination ◽

Markov Chain Models

Download Full-text

Nurses’ and midwives’ knowledge, attitudes, and acceptance regarding human papillomavirus vaccination in Ghana: a cross-sectional study

BMC Nursing ◽

10.1186/s12912-020-00530-x ◽

2021 ◽

Vol 20 (1) ◽

Author(s):

Nancy Innocentia Ebu ◽

Gifty Esinam Abotsi-Foli ◽

Doreen Faakonam Gakpo

Keyword(s):

Risk Factors ◽

Cervical Cancer ◽

Human Papillomavirus ◽

Hpv Vaccination ◽

Cross Sectional Study ◽

Sectional Study ◽

Cross Sectional ◽

Cancer Risk Factors ◽

Cervical Cancer Risk ◽

Nurses And Midwives

Abstract Background Nurses and midwives play important roles in educating the public on cervical cancer prevention strategies. Aim This study sought to assess nurses’ and midwives’ knowledge of, attitudes towards, and acceptance of human papillomavirus (HPV) vaccination in relation to their background characteristics. Methods A descriptive cross-sectional study using questionnaires was conducted with a convenience sample of 318 female nurses and midwives, ages 20 to 59, at the Korle-Bu Teaching Hospital in Ghana. The data were summarised using frequencies, percentages, chi-square tests, and Fisher’s exact tests. Results The results indicated that 41.5% (n = 132) of the participants had high levels of knowledge about cervical cancer risk factors, and 17.6% (n = 56) of the respondents had received at least one dose of the HPV vaccine. Reasons for receiving the HPV vaccination included advice from a colleague (12.9%, n = 41) and perceived threat of cervical cancer (11.7%, n = 37). Of the 262 respondents who had not been vaccinated, 24.45% (n = 78) strongly agreed and 28.0% (n = 89) agreed with the statement that there was limited information on HPV vaccination. Also, there were statistically significant associations between age (X2 = 23.746, p = 0.001), marital status (X2 = 14.758, p = 0.005), completed level of education (X2 = 21.692, p = 0.001), and duration of working at the hospital (X2 = 8.424, p = 0.038) and acceptance of HPV vaccination. Conclusions This study demonstrated gaps in knowledge about cervical cancer risk factors and attitudes towards HPV vaccination, indicating the need for targeted measures to improve knowledge and attitudes. Also, measures to increase acceptance of HPV vaccination among nurses and midwives should consider their sociodemographic characteristics.

Download Full-text

Modeling the impact of screening policy and screening compliance on incidence and mortality of cervical cancer in the post-HPV vaccination era

Journal of Public Health ◽

10.1093/pubmed/fds040 ◽

2012 ◽

Vol 34 (4) ◽

pp. 539-547 ◽

Cited By ~ 11

Author(s):

B. F. de Blasio ◽

A. R. Neilson ◽

M. Klemp ◽

F. E. Skjeldestad

Keyword(s):

Cervical Cancer ◽

Hpv Vaccination ◽

Screening Policy ◽

Incidence And Mortality ◽

The Impact

Download Full-text

Stakeholders’ Understandings of Human Papillomavirus (HPV) Vaccination in Sub-Saharan Africa: A Rapid Qualitative Systematic Review

Vaccines ◽

10.3390/vaccines9050496 ◽

2021 ◽

Vol 9 (5) ◽

pp. 496

Author(s):

Caroline Deignan ◽

Alison Swartz ◽

Sara Cooper ◽

Christopher J. Colvin

Keyword(s):

Systematic Review ◽

Cervical Cancer ◽

Human Papillomavirus ◽

Hpv Vaccine ◽

Hpv Vaccination ◽

Sub Saharan Africa ◽

African Countries ◽

Qualitative Systematic Review ◽

Sub Saharan ◽

And Gender

Cervical cancer rates in Sub-Saharan Africa (SSA) are amongst the highest worldwide. All three of the Human Papillomavirus (HPV) vaccines (9-valent, quadrivalent and bivalent HPV vaccine) provide primary protection against the most common cancer-causing strains of HPV (types 16 and 18) that are known to cause 70% of cervical cancers. Over the last five years, there has been an increase in Sub-Saharan African countries that have introduced the HPV vaccine. The majority of research has been conducted on supply-side barriers and facilitators to HPV vaccination uptake in SSA, yet little research has been conducted on demand-side or end-user perspectives of, and decisions around, HPV vaccination. In order to complement existing research, and inform current and future HPV vaccination implementation approaches, this qualitative systematic review explored Stakeholders’ understandings of HPV vaccination in SSA. This review searched the following databases: Embase (via Scopus), Scopus, MEDLINE (via PubMed), PubMed, EBSCOhost, Academic Search Premier, Africa-Wide Information, CINAHL, PsycARTICLES, PsycINFO, SocINDEX, Web of Science, and the Cochrane Controlled Register of Trials (CENTRAL) and found a total of 259 articles. Thirty-one studies were found eligible for inclusion and were analyzed thematically using Braun and Clarke’s methods for conducting a thematic analysis. The quality of included studies was assessed using the Critical Appraisal Skills Programme (CASP) checklist. Three major themes emerged from this analysis; knowledge of HPV vaccination and cervical cancer is intertwined with misinformation; fear has shaped contradictory perceptions about HPV vaccination and gender dynamics are relevant in how stakeholders understand HPV vaccination in SSA.

Download Full-text

The Pittsburgh Cervical Cancer Screening Model: A Risk Assessment Tool

Archives of Pathology & Laboratory Medicine ◽

10.5858/134.5.744 ◽

2010 ◽

Vol 134 (5) ◽

pp. 744-750

Author(s):

R. Marshall Austin ◽

Agnieszka Onisko ◽

Marek J. Druzdzel

Keyword(s):

Cervical Cancer ◽

Cancer Screening ◽

Cervical Cancer Screening ◽

Disease Risk ◽

Hpv Vaccination ◽

Dynamic Bayesian Network ◽

Adenocarcinoma In Situ ◽

Test Results ◽

Hpv Test

Abstract Context.—Evaluation of cervical cancer screening has grown increasingly complex with the introduction of human papillomavirus (HPV) vaccination and newer screening technologies approved by the US Food and Drug Administration. Objective.—To create a unique Pittsburgh Cervical Cancer Screening Model (PCCSM) that quantifies risk for histopathologic cervical precancer (cervical intraepithelial neoplasia [CIN] 2, CIN3, and adenocarcinoma in situ) and cervical cancer in an environment predominantly using newer screening technologies. Design.—The PCCSM is a dynamic Bayesian network consisting of 19 variables available in the laboratory information system, including patient history data (most recent HPV vaccination data), Papanicolaou test results, high-risk HPV results, procedure data, and histopathologic results. The model's graphic structure was based on the published literature. Results from 375 441 patient records from 2005 through 2008 were used to build and train the model. Additional data from 45 930 patients were used to test the model. Results.—The PCCSM compares risk quantitatively over time for histopathologically verifiable CIN2, CIN3, adenocarcinoma in situ, and cervical cancer in screened patients for each current cytology result category and for each HPV result. For each current cytology result, HPV test results affect risk; however, the degree of cytologic abnormality remains the largest positive predictor of risk. Prior history also alters the CIN2, CIN3, adenocarcinoma in situ, and cervical cancer risk for patients with common current cytology and HPV test results. The PCCSM can also generate negative risk projections, estimating the likelihood of the absence of histopathologic CIN2, CIN3, adenocarcinoma in situ, and cervical cancer in screened patients. Conclusions.—The PCCSM is a dynamic Bayesian network that computes quantitative cervical disease risk estimates for patients undergoing cervical screening. Continuously updatable with current system data, the PCCSM provides a new tool to monitor cervical disease risk in the evolving postvaccination era.

Download Full-text

Effect of a cervical cancer survivor story on willingness and behavioral change for Human Papillomavirus Vaccination: Randomized Controlled Trial (Preprint)

10.2196/preprints.34715 ◽

2021 ◽

Author(s):

Yukio Suzuki ◽

Akiko Sukegawa ◽

Yutaka Ueda ◽

Masayuki Sekine ◽

Takayuki Enomoto ◽

...

Keyword(s):

Cervical Cancer ◽

Randomized Controlled Trial ◽

Human Papillomavirus ◽

Cancer Survivor ◽

Controlled Trial ◽

Hpv Vaccination ◽

Intervention Group ◽

Control Group ◽

Randomized Controlled ◽

Cervical Cancer Survivor

BACKGROUND Providing adequate information to parents who have children eligible for human papillomavirus (HPV) vaccination is essential to overcoming vaccine hesitancy in Japan, where the government recommendation has been suspended. However, prior trials assessing the effect of brief educational tools showed only limited effects on increasing the willingness of parents to vaccinate their daughters. OBJECTIVE The aim of this trial was to assess the effect of a cervical cancer survivor story on the willingness of parents to get HPV vaccination for their daughters. METHODS In this double-blinded, randomized controlled trial implemented online, we enrolled 2175 participants aged 30–59 years in March 2020 via a webpage and provided them with a questionnaire related to the following aspects: awareness regarding HPV infection and HPV vaccination, and willingness for HPV vaccination. Participants were randomly assigned (1:1) to see a short film of cervical cancer survivor story or nothing, stratified by sex (male vs. female) and willingness to HPV vaccination prior to randomization (Yes vs. No). The primary endpoint was the rate of parents who agreed to HPV vaccination for their daughters. The secondary endpoint was the rate of parents who agreed to HPV vaccination for their daughters and the HPV vaccination rate at 3 months. RESULTS Among 2175 participants, 1266 (58.2%) were men and 909 (41.8%) were women. A total of 191 (8.8%) participants were willing to consider HPV vaccination prior to randomization. Only 339 (15.6%) participants were aware of the benefits of HPV vaccination. In contrast, 562 (25.8%) patients were aware of the adverse events of HPV vaccination. Although only 476 (21.9%) of the respondents displayed a willingness to vaccinate their daughters for HPV, there were 7.5% more respondents in the intervention group with this willingness immediately after watching the short movie (odds ratio [OR] 1.55, 95% CI 1.27-1.91). In a sub-analysis, the willingness to vaccinate daughters for HPV was 10.9% higher in males in the intervention group (OR 1.75, 95% CI 1.36-2.25); however, such a difference was not observed among females (OR 1.25, 95% CI 0.86-1.81). Male participants were more likely to have willingness for HPV vaccination compared to female participants. In the follow-up survey at 3 months, 1807 (83.1%) participants responded. Of these, 149 (8.2%) responded that they had had their daughters receive vaccination during the 3 months, even though we could not see the effect of the intervention; 77 (7.9%) in the intervention group and 72 (8.7%) in the control group. CONCLUSIONS A cervical cancer survivor story increases immediate willingness to consider HPV vaccination, but the effect does not last for 3 months. Furthermore, this narrative approach to parents did not increase vaccination rates in children eligible for HPV vaccination. CLINICALTRIAL UMIN Clinical Trials Registry UMIN000039273; https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000043714.

Download Full-text

Prevalence of human papillomavirus by geographical regions, sexual orientation and HIV status in China: a systematic review and meta-analysis

Sexually Transmitted Infections ◽

10.1136/sextrans-2017-053412 ◽

2018 ◽

Vol 94 (6) ◽

pp. 434-442 ◽

Cited By ~ 13

Author(s):

Xiaomeng Ma ◽

Qian Wang ◽

Jason J Ong ◽

Christopher K Fairley ◽

Shu Su ◽

...

Keyword(s):

Systematic Review ◽

Cervical Cancer ◽

Human Papillomavirus ◽

Meta Analysis ◽

Hpv Vaccination ◽

Hpv Infection ◽

Central China ◽

Hiv Positive ◽

Heterosexual Men ◽

Hpv Prevalence

ObjectiveHuman papillomavirus (HPV) infection causes multiple cancers in both women and men. In China, both HPV vaccination and cervical cancer screening coverages are low. We aim to investigate the temporal and geographical trends of HPV DNA prevalence in heterosexual men, women, men who have sex with men (MSM) and people living with HIV (PLHIV) in China.MethodsWe conducted a systematic review, collecting publications in PubMed, Web of Science, China National Knowledge Infrastructure (CNKI) and Wanfang Data from January 2000 to May 2017. A total of 247 studies were selected for this meta-analysis to estimate pooled HPV prevalence, incidence of cervical cancer and risk of infection for subgroups. Meta-regression was applied to identify contributing factors to prevalence heterogeneities.ResultsThe national HPV prevalence was 15.6% (95% CI (14.4% to 16.9%)) in women with normal cervical cytology, and Central China had the highest prevalence (20.5% (15.2% to 25.8%)). HPV prevalence in heterosexual men (14.5% (11.3% to 17.7%)) was comparable with that of women (OR=1.09 (0.98 to 1.17)), but HPV prevalence in MSM (59.9% (52.2% to 67.6%)) was significantly higher than that in heterosexual men (OR=8.81 (8.01 to 9.69)). HIV-positive women (45.0% (38.4% to 51.6%)) and HIV-positive MSM (87.5% (82.3% to 90.9%)) had 4.67 (3.61 to 6.03) and 6.46 (5.20 to 8.02) times higher risk of HPV infection than their HIV negative counterparts.ConclusionHPV infection is prevalent in China, particularly in Central China, in comparison with the global level and neighbouring countries. Targeted HPV vaccination for women, MSM and PLHIV and scale-up of cervical screening for women are priorities in curbing the HPV epidemic in China.

Download Full-text